Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy

Publikation: Bidrag til tidsskriftLederForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 696 KB, PDF-dokument

  • Korneliusz Golebski
  • Lente H. M. Dankelman
  • Sofia Björkander
  • Paul Brinkman
  • Antoine Deschildre
  • Yoni E. van Dijk
  • Louise Fleming
  • Jonathan Grigg
  • Eckard Hamelmann
  • Simone Hashimoto
  • Michael Kabesch
  • Susanna Klevebro
  • Anke-Hilse Maitland-Van der Zee
  • Simon K Merid
  • Antonio Nieto
  • Jakob Niggel
  • Caroline Nilsson
  • Uroš Potočnik
  • Graham Roberts
  • Franca Rusconi
  • Sejal Saglani
  • Elisangela Valente
  • Cornelis van Drunen
  • Gang Wang
  • Erik Melén
  • Susanne J. H. Vijverberg
OriginalsprogEngelsk
Artikelnummer00381-2021
Tidsskrift ERJ Open Research
Vol/bind7
Udgave nummer4
Antal sider6
ISSN2312-0541
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
Conflict of interest: K. Golebski received funds from STIMAG and from the Amsterdam Infection & Immunity Institute. L.H.M. Dankelman has nothing to disclose. S. Björkander has nothing to disclose. K. Bønnelykke has nothing to disclose. P. Brinkman has nothing to disclose. A. Deschildre has nothing to disclose. Y.E. van Dijk has nothing to disclose. L. Fleming reports grants from Asthma UK, and speakers fees or fees for expert consultation from Teva, AstraZeneca, Sanofi, Respiri and Novartis; all fees paid directly to her institution and outside the submitted work. J. Grigg reports personal fees from GSK, AstraZeneca and Novartis during the conduct of the study. E. Hamelmann has nothing to disclose. S. Hashimoto has nothing to disclose. M. Kabesch has nothing to disclose. S. Klevebro has nothing to disclose. A-H. Maitland-van der Zee has received research grants outside the submitted work from GSK, Boehringer Ingelheim and Vertex; she is the principal investigator of a P4O2 (Precision Medicine for more Oxygen) public–private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis); and she has served in advisory boards for AstraZeneca, GSK and Boehringer Ingelheim with money paid to her institution. S.K. Merid has nothing to disclose. A. Nieto reports grants and personal fees from Novartis outside the submitted work. J. Niggel has nothing to disclose. C. Nilsson has nothing to disclose. U. Potocnik reports grants from the Ministry of Education, Science and Sport. G. Roberts reports grants from the EU during the conduct of the study. F. Rusconi has nothing to disclose. S. Saglani has nothing to disclose. E. Valente has nothing to disclose. C. van Drunen has nothing to disclose. G. Wang has nothing to disclose. E. Melén reports personal fees from AstraZeneca, Chiesi, Novartis and Sanofi (advisory board activities) outside the submitted work. S.J.H. Vijverberg reports grants from ZonMW during the conduct of the study.

Funding Information:
Support statement: The PERMEABLE consortium is supported by ZonMW (project number: 456008004), the Swedish Research Council (project number 2018-05619), the Ministry of Education, Science and Sport of the Republic of Slovenia (contract number C3330-19-252012), and the German Ministry of Education and Research (BMBF) (project number FKZ01KU1909A), under the frame of the ERA PerMed JTC 2018 Call. Funding information for this article has been deposited with the Crossref Funder Registry.

ID: 301489994